MAKO Surgical (NAS: MAKO) is swimming in cash following a secondary equity offering of about 3 million shares. The offering priced at $13.15 per share, and after a hefty 6% underwriting discount (the fee made by the bank managing the offering), nets the company just over $40 million. The offering announcement came yesterday after the market closed, but it probably didn't come as a shock to some investors. Something fishy was going on yesterday, as MAKO shares fell nearly 10% on no meaningful news. Then came the official announcement. Once again, the individual investor is the last to know.

However, even with an impending offering announcement, it's unclear to me why shares sold off so sharply yesterday. The need for another capital raise has been a front-and-center issue for a number of quarters. With MAKO's cash balance sitting at only $28 million at the end of the third quarter, and the company burning cash at around $10 million a quarter, it was clear something would need to be done soon.

What remains unclear, and what might be behind the skittish response to the obvious rumors that were circulating yesterday, is timing. Why now? Sales execution was solid last quarter, with the company selling 15 RIO systems and calming heightened investor fears that MAKO was going the way of Hansen Medical (NAS: HNSN) , which emerged on the medical robotics scene to great fanfare only to disappoint in a big way. If trends were truly moving back in the right direction, why not hold off until next quarter?


A bird in the hand is worth two in the bush
The answer could be as simple as the old adage above. With the level of volatility that markets have exhibited since the election, investors also have to understand the systematic, or broader market, risks that can also impact a future equity offering. MAKO needed to raise capital, and it matters little whether it was this month or two months from now. If you're a long-term MAKO bull, you shouldn't be discouraged by the news, as the additional cash should buy the company at least another 18 months.

This could be the final equity offering MAKO ever has to do. However, the company will have to execute extremely well in order for that to become a reality. If you're interested in the full MAKO story, Fool.com analyst and MAKO expert David Meier has authored a premium research report covering all of the must-know details on the company, including key areas to watch and risks looming in the future. As an added bonus, David will keep you informed with a full year of updates and guidance on MAKO Surgical as news breaks. Click here now to learn more and start reading.

The article Hot off the Press: MAKO Grabs Some Dinero originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of MAKO Surgical. Motley Fool newsletter services recommend Hansen Medical and MAKO Surgical . Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Small Cap Investing

Learn now to invest in small companies the right way.

View Course »

Asset Allocation

Learn the most important step in structuring an investment portfolio.

View Course »

Add a Comment

*0 / 3000 Character Maximum

1 Comment

Filter by:
Don M

They face a $1M Non-use fee if they don't tap their Deerfield Line of Credit by the end of Q1. Better to raise the cash now then both having a share offering AND tapping the line in Q1. That would raise questions. Now, it's business as normal and they just got named the #1 fastest growing medical device company by Deloitte in their 2012 Fastest Growing 500 and #18 overall.

November 14 2012 at 12:09 PM Report abuse rate up rate down Reply